Recombinant Human BTNL3 Fc Chimera Protein, CF

Recombinant Human BTNL3 Fc Chimera (Catalog # 9658‑BT) inhibits IFN‑gamma secretion by human peripheral blood mononuclear cells in thepresence of anti-CD3 antibody. The ED50 for this effect is 1‑6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTNL3 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1-6 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human BTNL3 protein
  

  Human BTNL3 (Gln18-Ser237) Accession # Q6UXE8-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6UXE8-1
• N-terminal Sequence: No results obtained. Gln18 inferred from enzymatic pyroglutamate treatment revealing Trp19
• Structure / Form:

  Disulfide-linked homodimer

• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 53-63 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTNL3 Fc Chimera Protein, CF

• BTN9.1
• BTNL3
• BTNLR
• BTNLRButyrophilin-like receptor
• butyrophilin-like 3
• butyrophilin-like protein 3
• COLF4100

Background

Butyrophilin-like 3 (BTNL3) is a member of the BTN/MOG Ig-superfamily which is coded by the BTNL3 gene, also known as COLF4100 (1). BTNL3 is a 466 amino acid (aa) type I transmembrane protein that contains a 220 aa extracellular domain (ECD), a 21 aa helical transmembrane domain, and a 208 aa cytoplasmic domain. The ECD features both an IgV and IgC domain, which is commonplace in BTN/BTNL proteins, but the IgC domain is relatively weak (2-5). The ECD of human BTNL3 shares only 37% and 34% aa sequence identity with mouse (referred to as BTNL1) and rat, respectively. Human BTNL3 mRNA has been identified in many tissues including small intestine, colon, liver, lung, bone marrow and spleen tissue, and it is highly expressed in neutrophils (2-6). BTNL3 expression has also been found to be down-regulated in colon cancer tumors (7). The specific function of BTNL3, however, has yet to be fully elucidated. R&D in house data indicate that BTNL3 protein inhibits the secretion of IFN-gamma from anti-CD3 activated human T cells.

1. Shibui, A. et al. (1999) J. Hum. Genet. 44:249.
2. Arnett, H.A. et al. (2014) Nat Rev Immunol. 14:5596.
3. Arnett, H.A. et al. (2009) Cytokine 46:370.
4. Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
5. Rhodes, D. et al. (2016) Annu. Rev. Immunol. 34:151.
6. Guo, Y and Wang, AY (2015) Front. Immunol. 6:421.
7. Lebrero-Fernandez, C. et al. (2016) Immun. Inflammation Dis. 4:191.

Bioinformatics

• Uniprot:
  • Q6UXE8-1()